NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) is expected to be issuing its results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.4726) per share and revenue of $1.8770 million for the quarter.
NewAmsterdam Pharma Stock Performance
NASDAQ NAMSW opened at $15.00 on Wednesday. NewAmsterdam Pharma has a fifty-two week low of $10.27 and a fifty-two week high of $30.45. The stock has a 50 day simple moving average of $20.90 and a two-hundred day simple moving average of $21.72.
Institutional Trading of NewAmsterdam Pharma
A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 15,708 shares of the company’s stock, valued at approximately $397,000.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon?like peptide?1 (GLP-1) receptor agonist currently in early clinical trials.
See Also
- Five stocks we like better than NewAmsterdam Pharma
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
